BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2023-11
228 industry Phase 2/3 trial readout(s) and 23 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2023-11 | P2 | OPKO Health, Inc. OPK | NCT02500316 Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children | Growth Hormone Deficiency (GHD) | completed | 48 |
| 2023-11 est. | P3 | Lightpoint Medical Limited | NCT03731026 The LightPath® and 68Ga-RM2 in Breast Cancer Study | Breast Cancer | unknown | 80 |
| 2023-11 est. | P3 | EMS | NCT03814109 Efficacy and Safety of Leningrado Association in the Treatment of Hypertension | Arterial Hypertension | withdrawn | |
| 2023-11 est. | P1/P2 | Actinium Pharmaceuticals ATNM | NCT03867682 Venetoclax and Lintuzumab-Ac225 in AML Patients | Acute Myeloid Leukemia; Relapsed Adult AML | unknown | 38 |
| 2023-11 est. | P2 | Mucpharm Pty Ltd | NCT03976973 BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei | Pseudomyxoma Peritonei; Peritoneal Cancer; Mucinous Adenocarcinoma; Mucinous Tumor | unknown | 62 |
| 2023-11 est. | P2 | TaiwanJ Pharmaceuticals Co., Ltd | NCT04371718 Effect of JKB-122 on Prednisolone and Azathioprine Induced Remission in Autoimmune Hepatitis (AIH) | Autoimmune Hepatitis | unknown | 120 |
| 2023-11 est. | P3 | pH Pharma | NCT04863365 A Study of Efficacy and Safety of PHP-201 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension | Primary Open Angle Glaucoma; Ocular Hypertension | unknown | 110 |
| 2023-11 est. | P1/P2 | AlaMab Therapeutics (Shanghai) Inc. | NCT04886765 A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma | Osteosarcoma | unknown | 238 |
| 2023-11 est. | P2 | National Vaccine and Serum Institute, China | NCT05033847 Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years | COVID-19 Pneumonia; Coronavirus Infections | unknown | 1800 |
| 2023-11 est. | P2 | CSPC Ouyi Pharmaceutical Co., Ltd. | NCT05047991 Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic A | Pancreatic Cancer Non-resectable; Pancreatic Cancer Metastatic | unknown | 153 |
| 2023-11 est. | P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT05100329 A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer | Advanced Pancreatic Cancer | unknown | 38 |
| 2023-11 est. | P1/P2 | Ribon Therapeutics, Inc. | NCT05127590 RBN-2397 in Combination With Pembrolizumab in Patients With SCCL | Advanced Squamous Non-Small Cell Lung Carcinoma | unknown | 50 |
| 2023-11 est. | P1/P2 | Adaptive Phage Therapeutics, Inc. | NCT05269121 Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections | Prosthetic Joint Infection; Bacterial Infections | withdrawn | |
| 2023-11 est. | P2 | Vanda Pharmaceuticals VNDA | NCT05344365 A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis | Parkinson Disease Psychosis | withdrawn | |
| 2023-11 est. | P2/P3 | Frontier Biotechnologies Inc. ULCC | NCT05445934 Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study) | COVID-19 | unknown | 1188 |
| 2023-11 est. | P1/P2 | Tracon Pharmaceuticals Inc. | NCT05448820 YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma | Advanced Sarcoma; Metastatic Sarcoma; Soft Tissue Sarcoma | unknown | 15 |
| 2023-11 est. | P3 | DoCare Pharmaceutial Technology Co.,Ltd | NCT05764668 Efficacy and Safety of Zihua Wenfei Granules in Treatment of Postinfectious Cough (Wind-cold Invading Lungs Syndrome) | Cough | unknown | 480 |
| 2023-11 est. | P1/P2 | Context Therapeutics Inc. CNTX | NCT06938711 A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer | Breast Cancer | withdrawn | |
| 2023-11-01 | P1/P2 | Boehringer Ingelheim | NCT03861234 A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD) | Wet Macular Degeneration | completed | 43 |
| 2023-11-01 | P2 | Shanghai HEP Pharmaceutical Co., Ltd. | NCT04426968 A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B | Hepatitis B, Chronic | completed | 96 |
| 2023-11-01 est. | P1/P2 | Nature Cell Co. Ltd. | NCT04527224 Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia | Covid19 Pneumonia | unknown | 10 |
| 2023-11-01 | P2 | Seagen, a wholly owned subsidiary of Pfizer | NCT04579380 Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations | Uterine Neoplasms; Uterine Cervical Neoplasms; Biliary Tract Neoplasms; Urologic Neoplasms; Carcinom | active not recruiting | 217 |
| 2023-11-01 | P3 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | NCT04647526 Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment | Metastatic Castration-Resistant Prostate Cancer | active not recruiting | 455 |
| 2023-11-01 | P3 | Resilient Pharmaceuticals | NCT04714359 A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD | PTSD | completed | 87 |
| 2023-11-01 est. | P1/P2 | Jiangsu Yahong Meditech Co., Ltd aka Asieris | NCT04813107 A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients | Muscle Invasive Bladder Cancer | unknown | 79 |
| 2023-11-01 | P2 | Neuren Pharmaceuticals Limited | NCT05025241 An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001) | Phelan-McDermid Syndrome | completed | 18 |
| 2023-11-01 | P3 | Dong-A ST Co., Ltd. | NCT05282069 A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder | Overactive Bladder | completed | 607 |
| 2023-11-01 est. | P2 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | NCT05348122 A Study of TG103 Injection in Type 2 Diabetes Subjects | Type 2 Diabetes Mellitus | unknown | 240 |
| 2023-11-01 | P3 | Allergy Therapeutics | NCT05540717 Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen | Seasonal Allergic Rhinitis; Rhinoconjunctivitis | completed | 555 |
| 2023-11-01 | P3 | Kalbe International Pte. Ltd | NCT06128694 Effect of NUTRICAN to Improve Nutritional Status in Cancer Patients | Malnutrition; Protein; Cancer, Lung; Cancer Cervix | unknown | 108 |
| 2023-11-01 | P1/P2 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | NCT06302374 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults | Tetanus | completed | 202 |
| 2023-11-02 | P3 | Ascendis Pharma Endocrinology Division A/S ASND | NCT04615273 A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency | Growth Hormone Deficiency; Endocrine System Diseases; Hormone Deficiency | completed | 264 |
| 2023-11-02 | P2 | NeuroSense Therapeutics Ltd. NRSN | NCT05357950 A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of | Amyotrophic Lateral Sclerosis; ALS | completed | 69 |
| 2023-11-02 | P3 | Procter and Gamble PG | NCT05619328 A Prospective Clinical Trial to Evaluate the Efficacy and Safety of Neurotropic B-Vitamins in Clinically Diagnosed Peripheral Sensory Polyneuropathy of Differen | Peripheral Sensory Neuropathy of Different Etiologies | completed | 323 |
| 2023-11-02 | P3 | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | NCT06212973 A Study to Evaluate the Efficacy and Safety of Epinastine Hydrochloride Eye Drops in the Treatment of Chinese Seasonal Allergic Conjunctivitis Patients | Seasonal Allergic Conjunctivitis | completed | 266 |
| 2023-11-02 | P2 | Glaukos Corporation GKOS | NCT06582732 Performance of the Travoprost Intraocular Implant | Glaucoma, Open-Angle; Ocular Hypertension | completed | 210 |
| 2023-11-03 | P2/P3 | Incyte Corporation INCY | NCT03584516 GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | Chronic Graft-versus-host Disease | terminated | 155 |
| 2023-11-03 | P2 | RemeGen Co., Ltd. | NCT04329429 A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer | Biliary Tract Cancer | unknown | 57 |
| 2023-11-03 | P2/P3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT04840485 Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis | Ankylosing Spondylitis | completed | 548 |
| 2023-11-03 | P3 | Iterum Therapeutics, International Limited | NCT05584657 Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women | Urinary Tract Infections; Cystitis | completed | 2229 |
| 2023-11-03 | P3 | Lyndra Inc. | NCT05779241 Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005 | Schizophrenia; Schizoaffective Disorder | completed | 83 |
| 2023-11-03 | P2 | Hipra Scientific, S.L.U | NCT05981846 A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years | SARS CoV 2 Infection; Influenza, Human | completed | 279 |
| 2023-11-05 | P3 | Boehringer Ingelheim | NCT04509674 EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction) | Myocardial Infarction | completed | 6522 |
| 2023-11-06 | P1/P2 | Bio-Thera Solutions | NCT04772105 Study of Two Multiple Intravitreal Doses of BAT5906 for Safety and Efficacy in Patients With Diabetic Macular Edema | Diabetic Macular Edema | completed | 60 |
| 2023-11-06 | P2 | Definium Therapeutics US, Inc. DFTX | NCT05200936 Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial | ADHD; Attention Deficit Disorder | completed | 53 |
| 2023-11-06 est. | P3 | GlaxoSmithKline | NCT05229068 A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their | Respiratory Syncytial Virus Infections | withdrawn | |
| 2023-11-06 | P1/P2 | Zhejiang Raygene Pharmaceuticals Co., Ltd | NCT06848556 Evaluate the Effect of Tirazamine on Primary Liver Cancer. | Hepato Cellular Carcinoma (HCC) | terminated | 16 |
| 2023-11-07 | P2 | Taiwan Liposome Company | NCT03754049 A Phase 2, Open Label, Pharmacokinetic (PK) Study of TLC599 in Subjects With Osteoarthritis of the Knee | Osteoarthritis of the Knee | completed | 102 |
| 2023-11-07 | P1/P2 | The Emmes Company, LLC | NCT03981549 Treatment of Central Retinal Vein Occlusion Using Stem Cells Study | Central Retinal Vein Occlusion | completed | 16 |
| 2023-11-07 | P2 | Mirum Pharmaceuticals, Inc. MIRM | NCT04524390 Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai | Biliary Atresia | completed | 75 |
| 2023-11-07 | P2 | AstraZeneca AZN | NCT05459688 Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124 | Hypertension | completed | 175 |
| 2023-11-07 | P1/P2 | AstraZeneca AZN | NCT05460273 A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) | Carcinoma, Non-Small-Cell Lung; Triple Negative Breast Cancer | active not recruiting | 119 |
| 2023-11-07 | P3 | Haisco-USA Pharmaceuticals, Inc. | NCT05478174 Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia | General Anesthesia | completed | 400 |
| 2023-11-07 | P3 | Gilead Sciences GILD | NCT05603143 Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness | COVID-19 | terminated | 468 |
| 2023-11-08 | P3 | Sobi, Inc. | NCT04516967 Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months | Immune Thrombocytopenia | completed | 75 |
| 2023-11-08 | P2 | Sanofi SNY | NCT04572841 Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS) | Sjögren's Syndrome; Sjogren's Syndrome | completed | 84 |
| 2023-11-08 | P2 | AstraZeneca AZN | NCT04610892 Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction | Coronary Heart Disease (CHD) | completed | 423 |
| 2023-11-08 | P3 | Alexion Pharmaceuticals, Inc. | NCT04622046 A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM | Symptomatic Transthyretin Amyloid Cardiomyopathy | completed | 25 |
| 2023-11-08 | P2 | Revalesio Corporation | NCT04693715 Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy | Stroke, Ischemic | completed | 83 |
| 2023-11-08 | P2 | KoBioLabs | NCT04911751 A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis | Psoriatic Plaque | completed | 80 |
| 2023-11-08 | P3 | LEO Pharma | NCT05259722 A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Se | Chronic Hand Eczema | completed | 513 |
| 2023-11-08 | P3 | Neurocrine Biosciences NBIX | NCT05654870 Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia | Schizophrenia | terminated | 8 |
| 2023-11-08 | P2 | Technoderma Medicines Inc. | NCT05802173 Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia | Alopecia, Androgenetic | completed | 71 |
| 2023-11-08 | P3 | Lissette Ariza Corredor | NCT06757452 The Effect of Supplementation with Curcuminoids for the Improvement of Musculoskeletal Conditions in Sedentary Adults | Sedentariness and Well-being | completed | 34 |
| 2023-11-09 | P1/P2 | Atara Biotherapeutics ATRA | NCT03283826 Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis | Primary Progressive Multiple Sclerosis; Secondary Progressive Multiple Sclerosis | terminated | 134 |
| 2023-11-09 | P1/P2 | Beacon Therapeutics BBT | NCT03316560 Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations | X-Linked Retinitis Pigmentosa | active not recruiting | 29 |
| 2023-11-09 | P2 | Bristol-Myers Squibb BMY | NCT03496168 Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER | Hypertrophic Cardiomyopathy | completed | 13 |
| 2023-11-09 | P3 | Otsuka Pharmaceutical Development & Commercialization, Inc. | NCT04109950 A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia | Schizophrenia | terminated | 463 |
| 2023-11-09 | P2 | Cassava Sciences, Inc. | NCT04388254 Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients | Alzheimer Disease | completed | 220 |
| 2023-11-09 | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT04574284 A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer | Advanced Endometrial Cancer | completed | 170 |
| 2023-11-09 | P3 | Novartis Pharmaceuticals NVS | NCT04652726 Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia | Familial Hypercholesterolemia - Heterozygous | completed | 141 |
| 2023-11-09 | P2 | Boehringer Ingelheim | NCT04771273 A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) | Non-alcoholic Steatohepatitis (NASH) | completed | 295 |
| 2023-11-09 | P2 | RemeGen Co., Ltd. | NCT04905212 A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy | IgA Nephropathy | terminated | 15 |
| 2023-11-09 | P3 | UCB Biopharma SRL | NCT05067335 A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis | Osteoporosis | completed | 327 |
| 2023-11-09 | P3 | Ionis Pharmaceuticals, Inc. IONS | NCT05139810 OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE) | Hereditary Angioedema | completed | 91 |
| 2023-11-09 | P2 | Hoffmann-La Roche | NCT05171777 A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation | Non-small Cell Lung Cancer | completed | 179 |
| 2023-11-09 | P2 | Jazz Pharmaceuticals JAZZ | NCT05733390 A Study of JZP541 in Adults With Irritability Associated With Autism Spectrum Disorder | Irritability Associated With Autism Spectrum Disorder; Autism Spectrum Disorder; ASD | withdrawn | |
| 2023-11-09 | P2 | Apnimed APMD | NCT05793684 AD816 Crossover Study | OSA; Obstructive Sleep Apnea | completed | 25 |
| 2023-11-10 | P2 | AstraZeneca AZN | NCT04039113 Tezepelumab COPD Exacerbation Study | Chronic Obstructive Pulmonary Disease (COPD) | completed | 337 |
| 2023-11-10 | P3 | Actelion | NCT04565990 A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study | Hypertension, Pulmonary | completed | 43 |
| 2023-11-10 | P1/P2 | Axolotl Biologix | NCT05092646 Evaluating Intra-articular Injection of Axolotl Ambient Compared to Saline in Subjects With Ankle Osteoarthritis | Ankle Osteoarthritis | terminated | 12 |
| 2023-11-10 | P2 | G1 Therapeutics, Inc. | NCT05113966 Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer | Triple Negative Breast Cancer | terminated | 30 |
| 2023-11-10 | P3 | Cytokinetics CYTK | NCT05186818 Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM | Obstructive Hypertrophic Cardiomyopathy (oHCM) | completed | 282 |
| 2023-11-10 | P2 | Janssen Research & Development, LLC | NCT05307692 A Study of Seltorexant in Participants With Probable Alzheimer's Disease | Alzheimer Disease | completed | 88 |
| 2023-11-11 | P3 | Novavax NVAX | NCT05875701 Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines | COVID-19 | completed | 147 |
| 2023-11-13 | P3 | Takeda TAK | NCT04759833 A Study of Prucalopride For Functional Constipation in Children and Teenagers | Constipation | terminated | 175 |
| 2023-11-13 | P3 | Agios Pharmaceuticals, Inc. AGIO | NCT04770753 A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT) | Non-Transfusion-dependent Alpha-Thalassemia; Non-Transfusion-dependent Beta-Thalassemia | active not recruiting | 194 |
| 2023-11-13 | P2 | IVIEW Therapeutics Inc. | NCT05816070 Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial Conjunctivitis | Acute Bacterial Conjunctivitis | completed | 129 |
| 2023-11-13 | P2 | Tarsus Pharmaceuticals, Inc. TARS | NCT05838170 Study of TP-04 in Participants With Papulopustular Rosacea | Papulopustular Rosacea | completed | 37 |
| 2023-11-14 | P3 | UCB Biopharma SRL | NCT03598790 A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis; Moderate to Severe Chronic Plaque Psoriasis | completed | 1353 |
| 2023-11-14 | P2 | Alexion Pharmaceuticals, Inc. | NCT04304144 A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis | AL Amyloidosis | completed | 25 |
| 2023-11-14 | P1/P2 | Stoke Therapeutics, Inc STOK | NCT04442295 An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome | Dravet Syndrome | completed | 62 |
| 2023-11-14 | P2 | Sanofi SNY | NCT04678856 Dupilumab in CRSsNP | Chronic Rhinosinusitis Without Nasal Polyps; Sinusitis; Chronic Sinusitis; Sinus Disorder; Respirato | completed | 71 |
| 2023-11-14 | P3 | Novo Nordisk A/S NVO | NCT05013229 A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People | Diabetes Mellitus, Type 2 | completed | 679 |
| 2023-11-14 | P2 | Ascletis Pharmaceuticals Co., Ltd. | NCT05107778 Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV | Hepatitis B, Chronic | completed | 43 |
| 2023-11-14 | P1/P2 | LaNova Australia Pty Limited | NCT05188664 Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors | Advanced Solid Tumor | completed | 20 |
| 2023-11-14 | P3 | Tonix Pharmaceuticals, Inc. TNXP | NCT05273749 A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia | Fibromyalgia | completed | 457 |
| 2023-11-14 | P2 | Hipra Scientific, S.L.U | NCT05305573 Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19. | SARS-CoV-2 Infection | completed | 26 |
| 2023-11-14 | P2 | Ensysce Biosciences ENSC | NCT06629402 Assessment of PF614 Effects on Experimental Pain in the Cold Pressure Test (PF614-201) | Acute Pain | completed | 16 |
| 2023-11-15 | P3 | Tian Medical Inc. | NCT03337620 Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine | Headache, Migraine | completed | 174 |
| 2023-11-15 | P1/P2 | Hutchmed HCM | NCT03903705 : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors | Advanced Solid Tumor | completed | 348 |
| 2023-11-15 | P3 | LIB Therapeutics LLC | NCT04797247 Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction | Cardiovascular Diseases; Hyper-LDL-cholesterolemia | unknown | 900 |
| 2023-11-15 | P3 | LIB Therapeutics LLC | NCT04806893 Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction | Cardiovascular Risk Factor; Cardiovascular Diseases; Cardiovascular Stroke; Hypercholesterolemia | unknown | 900 |
| 2023-11-15 | P2 | Vertero Therapeutics | NCT04895215 AB-2004 in Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) | Autism Spectrum Disorder (ASD) | completed | 156 |
| 2023-11-15 | P3 | Celgene | NCT05028634 Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated I | Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | completed | 63 |
| 2023-11-15 est. | P3 | OncXerna Theraputics, Inc. | NCT05043402 A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer | Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma | unknown | 400 |
| 2023-11-15 | P3 | Mikrobiomik Healthcare Company S.L. | NCT05201079 Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin | Recurrent Clostridium Difficile Infection; Primary Clostridium Difficile Infection | completed | 93 |
| 2023-11-15 | P2/P3 | Novavax NVAX | NCT05975060 A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinate | COVID-19 | completed | 660 |
| 2023-11-16 | P2 | RECORDATI GROUP | NCT03606408 Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699 | Cushing's Syndrome | completed | 127 |
| 2023-11-16 | P2 | H. Lundbeck A/S | NCT05104476 A Study of Lu AF82422 in Participants With Multiple System Atrophy | Multiple System Atrophy | active not recruiting | 64 |
| 2023-11-16 | P1/P2 | Longboard Pharmaceuticals | NCT05364021 Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies | Developmental and Epileptic Encephalopathy; Dravet Syndrome; Lennox Gastaut Syndrome | completed | 52 |
| 2023-11-17 | P3 | Novo Nordisk A/S NVO | NCT01467427 Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B. | Congenital Bleeding Disorder; Haemophilia B | completed | 25 |
| 2023-11-17 | P1/P2 | Janssen Research & Development, LLC | NCT02908906 A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants Wit | Neoplasms | active not recruiting | 234 |
| 2023-11-17 | P3 | Otsuka Pharmaceutical Development & Commercialization, Inc. | NCT03393520 Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation | Agitation in Patients With Dementia of the Alzheimer's Type | completed | 601 |
| 2023-11-17 est. | P2 | Novartis Pharmaceuticals NVS | NCT04460729 A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases | Non-small Cell Lung Carcinoma (NSCLC) | withdrawn | |
| 2023-11-17 | P3 | Xenon Pharmaceuticals Inc. XENE | NCT04912856 An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE | Epilepsy; Epilepsy in Children; Epilepsy; Seizure; Disease; Brain Diseases; Central Nervous System D | terminated | 8 |
| 2023-11-17 | P2/P3 | ModernaTX, Inc. | NCT04927065 A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants | SARS-CoV-2 | completed | 5161 |
| 2023-11-17 | P2 | Hoffmann-La Roche | NCT04933227 A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gas | Stomach Neoplasms; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma | terminated | 29 |
| 2023-11-17 | P3 | Janssen Research & Development, LLC | NCT04951622 A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis | Myasthenia Gravis | recruiting | 199 |
| 2023-11-17 | P3 | Novo Nordisk A/S NVO | NCT04970654 A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day. | Growth Hormone Deficiency in Children | completed | 110 |
| 2023-11-17 | P3 | Alvotech Swiss AG ALVO | NCT05155293 Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE) | Neovascular (Wet) AMD | completed | 413 |
| 2023-11-17 | P3 | Sumitomo Pharma America, Inc. | NCT05227209 A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I | Depressive Episodes, Bipolar I Depression | terminated | 64 |
| 2023-11-17 | P1/P2 | InventisBio Co., Ltd | NCT05383898 Study to Evaluate D-1553 in Subjects With Lung Cancer | NSCLC | completed | 225 |
| 2023-11-17 | P2 | TrueBinding, Inc. | NCT05476783 A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease | Alzheimer's Disease | terminated | 119 |
| 2023-11-17 | P2 | AIM ImmunoTech Inc. AIM | NCT05592418 Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions | Post COVID-19 Condition; Long COVID | completed | 80 |
| 2023-11-19 | P3 | Biotest | NCT05170269 Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion) | Congenital Cytomegalovirus Infection | terminated | 48 |
| 2023-11-20 | P1/P2 | Akeso | NCT04444167 A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma | completed | 59 |
| 2023-11-20 | P3 | Novartis Pharmaceuticals NVS | NCT04486716 A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis | Relapsing Multiple Sclerosis | completed | 111 |
| 2023-11-20 | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT04590599 A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed | Advanced Cervical Cancer | completed | 205 |
| 2023-11-20 | P2 | Pfizer PFE | NCT05192200 An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study | Dermatomyositis | completed | 24 |
| 2023-11-20 | P3 | PharmaEssentia | NCT05231044 A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or Scalp | Actinic Keratosis | completed | 108 |
| 2023-11-20 | P2 | Rakuten Medical, Inc. | NCT05265013 ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases | Head and Neck Cancer | terminated | 16 |
| 2023-11-20 | P2 | Eli Lilly and Company LLY | NCT05516758 A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis | Rheumatoid Arthritis; Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Conne | terminated | 491 |
| 2023-11-20 | P1/P2 | ModernaTX, Inc. | NCT05827068 A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults | Seasonal Influenza | completed | 698 |
| 2023-11-21 | P3 | Celgene | NCT03440385 Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease | Crohn Disease | completed | 606 |
| 2023-11-21 | P3 | Janssen Research & Development, LLC | NCT03596645 A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | Colitis, Ulcerative | active not recruiting | 84 |
| 2023-11-21 | P3 | GlaxoSmithKline | NCT04318548 Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vacc | Infections, Meningococcal | completed | 945 |
| 2023-11-21 | P1/P2 | Tenet Medicines | NCT04652570 Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy | Membranous Nephropathy | terminated | 6 |
| 2023-11-21 | P3 | GlaxoSmithKline | NCT04719832 Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype | Asthma | completed | 395 |
| 2023-11-21 | P2 | Hoffmann-La Roche | NCT05009069 A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer | Rectal Neoplasms; Rectal Cancer | active not recruiting | 58 |
| 2023-11-21 | P2 | Lallemand Health Solutions | NCT05545813 Impact of Probiotic Supplementation on Cognition and Related Health Outcomes Among Video Gamers | Stress; Attention Disturbances | completed | 36 |
| 2023-11-21 | P2 | Daiichi Sankyo | NCT05569252 A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum | Pseudoxanthoma Elasticum | completed | 65 |
| 2023-11-21 | P2 | Supernus Pharmaceuticals, Inc. SUPN | NCT05645432 An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus | Tinnitus | completed | 10 |
| 2023-11-21 | P2 | Aldeyra Therapeutics, Inc. ALDX | NCT05717920 A Clinical Trial in Subjects With Atopic Dermatitis (Part 1) | Atopic Dermatitis | completed | 8 |
| 2023-11-21 | P2 | Empros Pharma AB | NCT05934110 Study Exploring the Supportive Effect of Acarbose in Weight Management | Overweight or Obesity | unknown | 320 |
| 2023-11-22 | P1/P2 | Janssen Vaccines & Prevention B.V. | NCT02935686 A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Alon | Healthy | completed | 155 |
| 2023-11-22 | P1/P2 | Takeda TAK | NCT03648372 A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System | Neoplasms; Lymphoma; Hematologic Neoplasms | terminated | 109 |
| 2023-11-22 | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT04808570 A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | terminated | 23 |
| 2023-11-22 | P3 | Allergan | NCT04891419 JUVÉDERM® VOLUMA® With Lidocaine for Correction of Temple Hollowing in Chinese Population | Temple Hollowing | completed | 168 |
| 2023-11-22 | P3 | Shanghai Bovax Biotechnology Co., Ltd. | NCT05027776 Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years | HPV Infections; Cervical Cancer Stage IIa; Vaginal Cancer; Genital Wart; CIN1; CIN2; CIN3 | unknown | 1348 |
| 2023-11-22 | P3 | Arthritis Innovation Corporation | NCT05603832 A Phase 3 Study of F14 for Management of Pain Following Total Knee Replacement | Post Operative Pain | completed | 151 |
| 2023-11-22 | P3 | Healthgen Biotechnology Corp. | NCT06355479 A Study to Evaluate the Efficacy and Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia | Hypoalbuminemia; Hepatic Cirrhosis | completed | 328 |
| 2023-11-22 | P2 | Wuhan Createrna Science and Technology Co., Ltd | NCT06920836 QR052107B Tablets in Patients With Subacute Cough of Phase Ⅱ Study | Cough | completed | 270 |
| 2023-11-23 | P3 | Novartis Pharmaceuticals NVS | NCT04838613 Study of Diagnostic Performance of [18F]CTT1057 in BCR | Prostatic Neoplasms; Prostate Cancer; Recurrence | completed | 190 |
| 2023-11-24 | P2 | Nykode Therapeutics ASA | NCT04405349 Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer | Cervical Cancer; Cervix Cancer | completed | 52 |
| 2023-11-24 | P2 | Janssen Vaccines & Prevention B.V. | NCT04765384 A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19) | COVID-19 Prevention | completed | 51 |
| 2023-11-24 | P3 | Estetra | NCT04792385 Safety, Compliance and Pharmacokinetics of Estetrol Monohydrate/Drospirenone 15/3 mg in Post-menarchal Female Adolescents | Safety | completed | 145 |
| 2023-11-24 | P2/P3 | Novartis Pharmaceuticals NVS | NCT04838626 Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection | Prostatic Neoplasms; Prostate Cancer | completed | 195 |
| 2023-11-24 | P3 | Pfizer PFE | NCT04927247 A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises | Sickle Cell Disease; Vaso-occlusive Crisis; Vaso-occlusive Pain Episode in Sickle Cell Disease | terminated | 72 |
| 2023-11-24 est. | P2/P3 | Peschke GmbH | NCT05255016 Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers | Keratitis; Corneal Ulcer | unknown | 488 |
| 2023-11-24 est. | P2/P3 | Peschke GmbH | NCT05255107 Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers | Keratitis; Corneal Ulcer | unknown | 468 |
| 2023-11-24 | P2/P3 | Seelos Therapeutics, Inc. | NCT05490563 STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia | Spinocerebellar Ataxia Type 3 | terminated | 23 |
| 2023-11-24 | P3 | Akeso | NCT05509361 Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis | Plaque Psoriasis | completed | 950 |
| 2023-11-24 | P2 | EpiEndo Pharmaceuticals | NCT05572333 Clinical Trial to Investigate the Safety and Tolerability of EP395 in Patients With COPD | Chronic Obstructive Pulmonary Disease; COPD | completed | 61 |
| 2023-11-24 | P2 | Lallemand Health Solutions | NCT06057883 Effects Of A Probiotic Formulation On Stress and Skin Health in Younger Adult Females | Stress; Skin Imperfections; Skin Fine Lines | completed | 35 |
| 2023-11-24 | P3 | Ocumension Therapeutics (Shanghai) Co., Ltd | NCT06429306 Study of Dexycu in Treating Intraocular Inflammation | Inflammation; Cataract | completed | 285 |
| 2023-11-27 | P2/P3 | REGENXBIO Inc. RGNX | NCT03566043 CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome) | Mucopolysaccharidosis Type II (MPS II) | active not recruiting | 48 |
| 2023-11-27 | P3 | Daewoong Pharmaceutical Co. LTD. | NCT04784910 Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer | Peptic Ulcer | completed | 423 |
| 2023-11-27 | P3 | Novartis Pharmaceuticals NVS | NCT04984876 Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy | Allergy, Peanut | terminated | 211 |
| 2023-11-27 | P1/P2 | SQZ Biotechnologies | NCT05357898 Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | Adult Solid Tumor | terminated | 20 |
| 2023-11-27 | P3 | Bristol-Myers Squibb BMY | NCT05414175 A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy | Cardiomyopathy, Hypertrophic Obstructive | completed | 38 |
| 2023-11-27 | P2 | Addpharma Inc. | NCT05631990 A Study to Evaluate the Efficacy and Safety of AD-209 | Hypertension, Essential | completed | 221 |
| 2023-11-27 | P2 | Formation Bio, Inc. | NCT05870865 A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis | Dermatitis, Atopic; Pruritus | completed | 144 |
| 2023-11-27 | P3 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | NCT06500689 To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil | Essential Hypertension | completed | 366 |
| 2023-11-28 | P1/P2 | MingSight Pharmaceuticals, Inc | NCT03492125 A Study Of The Selective PKC-β Inhibitor MS- 553 | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Aggressive Lymphoma | terminated | 60 |
| 2023-11-28 | P2 | Seagen Inc. | NCT04032704 A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Small Cell Lung Cancer; Non-small Cell Lung Cancer, Squamous; Non-small Cell Lung Cancer, Non-squamo | terminated | 205 |
| 2023-11-28 | P1/P2 | Galera Therapeutics, Inc. | NCT04476797 Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC | SBRT; NSCLC; Non-metastatic | terminated | 47 |
| 2023-11-28 | P1/P2 | Jounce Therapeutics, Inc. | NCT04669899 Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors | Cancer | completed | 190 |
| 2023-11-28 | P3 | Novartis Pharmaceuticals NVS | NCT04971226 A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive | active not recruiting | 405 |
| 2023-11-28 | P1/P2 | Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. | NCT05272813 A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL | Lymphocytic Leukemia; Small Lymphocytic Lymphoma | terminated | 13 |
| 2023-11-28 | P2 | Novartis Pharmaceuticals NVS | NCT05454410 Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD) | Treatment-Resistant Depression | completed | 60 |
| 2023-11-28 | P3 | Takeda TAK | NCT05460325 A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE) | Hereditary Angioedema (HAE) | completed | 20 |
| 2023-11-28 | P3 | Gilead Sciences GILD | NCT05715528 Study of Obeldesivir in Nonhospitalized Participants With COVID-19 | COVID-19 | completed | 2011 |
| 2023-11-28 | P1/P2 | MingSight Pharmaceuticals, Inc | NCT05720052 A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma | Relapsed or Refractory B-cell Lymphoma; Diffuse Large B-cell Lymphoma (DLBCL); Follicular Lymphoma ( | terminated | 8 |
| 2023-11-28 | P3 | Geropharm | NCT07070752 Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients | Type 1 Diabetes Mellitis | completed | 224 |
| 2023-11-29 | P2/P3 | SyneuRx International (Taiwan) Corp | NCT02261519 Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults | Schizophrenia | terminated | 280 |
| 2023-11-29 | P3 | AbbVie ABBV | NCT03047395 A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) | Psoriasis | completed | 2170 |
| 2023-11-29 | P1/P2 | Bridge Biotherapeutics, Inc. | NCT04820023 Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment | NSCLC | terminated | 45 |
| 2023-11-29 | P2 | EQRx, Inc. | NCT05085002 A Study of Lerociclib in Participants With Advanced Breast Cancer | Advanced Breast Cancer | terminated | 100 |
| 2023-11-29 | P3 | Allergan | NCT05088980 Study to Assess Effectiveness and Adverse Events of JUVEDERM VOLBELLA With Lidocaine Injection in Correcting Infraorbital Hollowing in Chinese Adult Participant | Infraorbital Hollowing | completed | 160 |
| 2023-11-29 | P3 | Gilead Sciences GILD | NCT05089734 Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Non-Small Cell Lung Cancer | active not recruiting | 603 |
| 2023-11-29 | P1/P2 | Chengdu Zenitar Biomedical Technology Co., Ltd | NCT05153343 Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative | Myeloproliferative Neoplasm (MPN); Myelofibrosis,MF | completed | 31 |
| 2023-11-29 | P2 | EyePoint Pharmaceuticals, Inc. EYPT | NCT05381948 Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) | Wet Age-related Macular Degeneration | completed | 161 |
| 2023-11-29 | P2 | Ensol Bioscience | NCT05697952 E1K Intra Articular(IA) Treatment for Knee Osteoarthritis | Osteoarthrosis | completed | 120 |
| 2023-11-29 | P2 | Caliway Biopharmaceuticals Co., Ltd. | NCT05836779 A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2) | Cellulite | completed | 23 |
| 2023-11-30 | P3 | Beta Pharma Shanghai | NCT03866499 A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients | NSCLC | unknown | 369 |
| 2023-11-30 | P3 | Seqirus | NCT03932682 Efficacy Study With QIVc in Pediatric Subjects | Influenza, Human | completed | 5723 |
| 2023-11-30 | P3 | Eurofarma Laboratorios S.A. | NCT03936218 Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer | Advanced Prostate Cancer | completed | 94 |
| 2023-11-30 est. | P3 | Incyte Corporation INCY | NCT04203511 INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301) | Non-small Cell Lung Cancer | withdrawn | |
| 2023-11-30 | P1/P2 | InSightec | NCT04417088 Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy | Recurrent Glioblastoma | completed | 28 |
| 2023-11-30 | P1/P2 | InSightec | NCT04440358 Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM | Recurrent Glioblastoma | completed | 13 |
| 2023-11-30 | P2 | Lumicell, Inc. | NCT04440982 Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients | Breast Cancer; Neoadjuvant Therapy | terminated | 98 |
| 2023-11-30 | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT04517357 A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients | Relapsed Ovarian Cancer | completed | 100 |
| 2023-11-30 | P3 | Savara Inc. SVRA | NCT04544293 Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | Autoimmune Pulmonary Alveolar Proteinosis | active not recruiting | 164 |
| 2023-11-30 | P2 | GlaxoSmithKline | NCT04544956 A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B | Hepatitis B | completed | 12 |
| 2023-11-30 est. | P1/P2 | Beijing InnoCare Pharma Tech Co., Ltd. | NCT04565275 A Study of ICP-192 in Patients With Advanced Solid Tumors | Advanced Solid Tumors; Urothelial Carcinoma; Cholangiocarcinoma | unknown | 45 |
| 2023-11-30 | P2 | Galera Therapeutics, Inc. | NCT04698915 Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer | SBRT; Borderline Resectable Pancreatic Cancer; Unresectable Pancreatic Cancer | terminated | 177 |
| 2023-11-30 | P1/P2 | THERAPIM PTY LTD | NCT04814875 A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy | Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma; High Grade Serious or Endometri | terminated | 16 |
| 2023-11-30 | P3 | Xiamen Amoytop Biotech Co., Ltd. | NCT04846491 A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B | Chronic Hepatitis B | completed | 475 |
| 2023-11-30 | P2 | Redx Pharma Ltd | NCT04907851 A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) | Advanced Solid Tumours | completed | 45 |
| 2023-11-30 | P2 | Endeavor Biomedicines, Inc. | NCT04968574 A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | completed | 41 |
| 2023-11-30 est. | P2 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT05138146 A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Tr | Sarcoma, Soft Tissue | unknown | 70 |
| 2023-11-30 | P2 | Alexion Pharmaceuticals, Inc. | NCT05218096 Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis | Generalized Myasthenia Gravis; Myasthenia Gravis | terminated | 70 |
| 2023-11-30 | P3 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT05347134 SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer | Triple Negative Breast Cancer | active not recruiting | 254 |
| 2023-11-30 | P2 | Janssen Scientific Affairs, LLC | NCT05347485 A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma | Multiple Myeloma | completed | 86 |
| 2023-11-30 est. | P2 | Aristea Therapeutics, Inc. | NCT05448391 A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF) | Familial Mediterranean Fever | withdrawn | |
| 2023-11-30 est. | P2 | DermBiont, Inc. | NCT05491603 A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis | Onychomycosis | suspended | 60 |
| 2023-11-30 | P3 | Handok Inc. | NCT05504226 Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin | Type 2 Diabetes | completed | 214 |
| 2023-11-30 | P2 | Oxular Limited | NCT05512962 Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema | Diabetic Macular Edema | completed | 25 |
| 2023-11-30 | P2/P3 | ACELYRIN Inc. | NCT05623345 Psoriatic Arthritis Study of Izokibep | Psoriatic Arthritis | terminated | 351 |
| 2023-11-30 est. | P3 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT05788588 A Phase Ⅲ Study of HR19006 Injection in Postsurgical Parenteral Nutrition | Parenteral Nutrition | unknown | 240 |
| 2023-11-30 | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT05849246 The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemother | Non-squamous Non-small-cell Lung Cancer | terminated | 4 |
| 2023-11-30 est. | P2 | AIM Vaccine Co., Ltd. | NCT05939648 A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) | SARS-CoV-2 | unknown | 450 |
| 2023-11-30 | P3 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | NCT05943977 A Bioequivalence and Efficacy Study of MB-102 (Relmapirazin) in Chinese Participants | Kidney Diseases; Kidney Injury; Kidney Failure | completed | 121 |
| 2023-11-30 | P2 | Samsung Bioepis Co., Ltd. | NCT06176963 A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO | Neovascular Age-related Macular Degeneration; Macular Edema; Retinal Vein Occlusion | completed | 34 |
| 2023-11-30 | P3 | Dobri Kiprov | NCT06534450 The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics | Aging | unknown | 40 |
| 2023-11-30 | P3 | Beijing Kawin Technology Share-Holding Co., Ltd. | NCT06544551 Efficacy and Safety Study of Peginterferon Alfacon-2 to Treat Chronic Hepatitis B Virus Infection | Chronic Hepatitis B Virus Infection | completed | 336 |
| 2023-11-30 | P3 | Changchun GeneScience Pharmaceutical Co., Ltd. | NCT06984159 The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Inj | Advanced Prostate Cancer | completed | 137 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.